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Abstract: Metagenomics was used to identify viral sequences in the plasma and CSF (cerobrospinal
fluid) of 13 horses with unexplained neurological signs and in the plasma and respiratory swabs of
14 horses with unexplained respiratory signs. Equine hepacivirus and two copiparvoviruses (horse
parvovirus-CSF and a novel parvovirus) were detected in plasma from neurological cases. Plasma
from horses with respiratory signs contained the same two copiparvoviruses plus equine pegivirus
D and respiratory swabs contained equine herpes virus 2 and 5. Based on genetic distances the
novel copiparvovirus qualified as a member of a new parvovirus species we named Eqcopivirus.
These samples plus another 41 plasma samples from healthy horses were tested by real-time PCRs
for multiple equine parvoviruses and hepacivirus. Over half the samples tested were positive for
one to three viruses with eqcopivirus DNA detected in 20.5%, equine hepacivirus RNA and equine
parvovirus-H DNA in 16% each, and horse parvovirus-CSF DNA in 12% of horses. Comparing viral
prevalence in plasma none of the now three genetically characterized equine parvoviruses (all in the
copiparvovirus genus) was significantly associated with neurological and respiratory signs in this
limited sampling.
Keywords: Parvoviridae; Eqcopivirus; horse parvovirus-CSF; equine hepacivirus; equine parvovirus H;
bosavirus; virome
1. Introduction
The United States has the largest horse population with 9.5 million horses, followed by those of
China, Mexico, Brazil, and Argentina with an estimated 2006 world population of 68 million [1].
Equine viral pathogens belonging to diverse viral families have been described including, but not
limited to, equid herpesviruses, equine arteritis virus, African horse sickness virus, equine infectious
anemia virus, equine coronavirus, Hendra virus, vesicular stomatitis virus, equine influenza virus, West
Nile virus, Eastern Equine Encephalitis, Venezuelan Equine Encephalitis, Western Equine Encephalitis,
and most recently equine parvovirus-H causing hepatitis [2–9].
A limited number of viral metagenomics studies have analyzed horse samples. A 2013 study
identified a novel flavivirus that was named Theiler’s disease-associated virus (TDAV) from an outbreak
of this liver disease transmitted through equine-origin tetanus anti-toxin [10]. Equine parvovirus-H in
the copiparvovirus genera (EqPV-H) was first described in 2018 [2] and was recently shown through
epidemiological studies and inoculation studies to be a more likely cause of Theiler’s disease caused
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either by transfusion of contaminated horse serum or through naturally acquired infections (although
asymptomatic infections are also frequent) [11–13]. A hepacivirus closely related to HCV (hepatitis
C virus), initially characterized by metagenomics from a dog [14], but subsequently found to more
frequently infect horses was named equine hepacivirus (EqHV) but was not associated with serum
hepatitis [15–17]. Equine pegivirus (EPgV), most closely related to a bat pegiviruses [18], was first
identified using a degenerate PCR approach [19] and shown to be a common equine infection but was
also not associated with equine liver disease [15].
Beside the above studies focused on Theiler’s disease viral metagenomics study of CSF from
a horse with neurological signs identified another parvovirus named horse parvovirus-CSF [20].
Metagenomics studies of equine serum pools recently identified the four equine viruses listed above
plus unexpectedly the porcine Suid betaherpesvirus 2 [21].
To further characterize the eukaryotic virome of horses and identify possible equine pathogens we
used here a combination of viral metagenomics and real-time PCR to analyze plasma and cerebrospinal
fluid (CSF) from 13 horses with unexplained neurological signs, plasma and respiratory swabs from 14
horses with unexplained respiratory signs, and plasma from 41 healthy horses, when necessary.
2. Materials and Methods
2.1. Study Samples
The use of horse samples adhered to the animal use guidelines set by UC Davis’ Institutional
Animal Care and Use Committee (AICUC Protocol # 19988, approval date 5/31/2018).
In this study 68 horses were analyzed using one or two of three types of biological samples
(plasma, CSF, and respiratory swabs). Both plasma and CSF were collected from 13 horses that showed
acute neurological signs (behavioral changes, spinal ataxia, proprioceptive deficits and/or cranial nerve
deficits). Plasma and respiratory swabs were collected from another 14 horses with fever (>38.6 ◦C)
and nasal discharge/cough (the respiratory swab from animal 5 is missing). Plasma was also collected
from 41 healthy horses.
The 13 horses with neurological signs each had CSF with evidence of lymphocytic pleocytosis,
negative antibody titters to Sarcocysits neurona and Neospora hughesi by immunodiagnostics (indirect
fluorescence antibody tests) and no detection of S. neurona, N. hughesi, and Borrelia burgdorferi by PCR.
The 13 horses with respiratory signs each had respiratory swabs that tested non-reactive for EHV-1/-4,
EIV, ERAV/ERBV, and Streptococcus equi subspecies equi.
All 53 samples from these 27 sick horses were analyzed in 12 pools of 4–5 samples using viral
metagenomics (Table 1).
Table 1. Distribution of translated sequence reads with similarity E score of <10−10 to known mammalian
viral proteins.
Disease and
Sample Types Total Reads
Equine
Hepacivirus
Equine
Pegivirus D
Equid
Gamma
Herpesvirus2
Equid
Gammaherpes
Virus5
Horse
Parvovirus-CSF
Novel
Parvovirus:
Eqcopivirus
Bosavirus
Neuro Pool1
Plasma 2,575,048 1023 17,058
Neuro Pool4
CSF 1,106,824
Neuro Pool2
Plasma 1,612,796 7
Neuro Pool5
CSF 1,028,398
Neuro Pool3
Plasma 2,080,966
Neuro Pool6
CSF 1,057,992
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Table 1. Cont.
Disease and
Sample Types Total Reads
Equine
Hepacivirus
Equine
Pegivirus D
Equid
Gamma
Herpesvirus2
Equid
Gammaherpes
Virus5
Horse
Parvovirus-CSF
Novel
Parvovirus:
Eqcopivirus
Bosavirus
Respiratory
Pool7 Plasma 1,509,792 317 36,069
Respiratory
Pool10 Swab 622,376 1719
Respiratory
Pool8 Plasma 603,470 1087 16,355
Respiratory
Pool11 Swab 949,260 120 25 880
Respiratory
Pool9 Plasma 1,520,736
Respiratory
Pool12 Swab 629,274 395
2.2. Viral Metagenomics
For viral metagenomics plasma, CSF, and respiratory swab samples were clarified by 14,000 rpm
centrifugation for five minutes, and filtered using a 0.45-µm filter (Merck Millipore Ltd., Cork, Ireland).
Free nucleic acids in the 400 µL filtrates were digested using DNAse and RNAse enzymes to enrich for
viral nucleic acids protected within viral capsids. Nucleic acids were then extracted (MagMAX Viral
RNA Isolation Kit, Ambion, Inc, Austin, TX, USA) [22] and amplified by random RT-PCR followed by
use of the Nextera™ XT Sample Preparation Kit (Illumina) to generate a library for Illumina MiSeq
(2 × 250 bases) with dual barcoding as previously described [23].
An in-house analysis pipeline was used to analyze sequence data. Before analyzing, raw data were
pre-processed by subtracting human and bacterial sequences, duplicate sequences, and low quality
reads. Following de novo assembly using the Ensemble program [24], both contigs and singlets viral
sequences were then analyzed using translated protein sequence similarity search (BLASTx v.2.2.7)
to all annotated viral proteins available in GenBank. Candidate viral hits were then compared to an
in-house non-virus non-redundant (nr) protein database to remove false positive viral hits. To align
reads and contigs to reference viral genomes from GenBank and generate complete or partial genome
sequences the Geneious R10 program was used.
2.3. Generation of Full Genomes of Novel Horse Parvovirus
Following mini-pool metagenomics sequencing three individual samples were re-sequenced
using the same method to generate 3 near full genomes (complete ORFs) of eqcopiviruses (EqCoPV)
(deposited in GenBank with accession numbers MN181466-8 for eqcopivirus 8, 9, and 11 derived from
respiratory symptoms plasma samples 4, 5, and 7 respectively). Genome gaps left by high throughput
sequencing (HTS) were filled by PCR and products were Sanger sequenced.
2.4. Real-Time PCR
Real-time PCR assays were developed to the three parvoviruses detected here using HTS
(horse parvovirus-CSF, novel eqcopivirus, and bovine serum-associated bosavirus). Real-time
PCR assays were also designed for equine hepaciviruses detected in one plasma pool and for the
recently identified hepatotropic equine parvovirus-H (EqPV-H) pathogen using previously described
PCR conditions [12,17]. Real-time PCR amplification was performed in a Roche 480 thermocycler.
Primers and probes were used in multiplex real-time PCR (eqcopivirus, horse parvovirus-CSF,
and bosavirus) and a separate multiplex real-time PCR for equine hepacivirus and EqPV-H. Primer,
probes, oligonucleotide sequences, and length of amplicons are summarized in Supplementary Table S1.
The reaction mix for each sample consisted of 12.5 µL QuantiFast Probe PCR Master Mix (Qiagen,
Hilden, Germany), 1M each primer, 0.5 M each probe, and 3 µL DNA or cDNA. Real-time PCR
sensitivity was first determined using known concentrations of oligonucleotides representing the PCR
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target regions. Oligonucleotides were serially diluted and real-time PCR results endpoint detection
were estimated at 100 to 125 input genome equivalents.
2.5. Phylogenetic Analysis
The NS1 and VP1 protein sequences of parvoviruses were aligned using Clustal W in Geneious
v10.1.3. and phylogenetic trees constructed using the Maximum likelihood method with two
substitution models: Le_Gascule_2008 model (LG) with Freqs and gamma distributed, invariant
sites (G + I) MEGA software ver. X [25]. The substitution models were selected based on the results
of the Best Model search of MEGA X. The percentage of trees in which the associated taxa clustered
together is shown next to the branch points. Initial tree(s) for the heuristic search were obtained by
applying the neighbor-joining method to a matrix of pairwise distances estimated using the maximum
composite likelihood (MCL) approach. The tree is drawn to scale, with branch lengths measured in the
number of substitutions per site. The phylogenetic analysis used sequences from nineteen different
copiparvoviruses and human parvovirus B19 (AY386330) was used to root the tree.
3. Results
3.1. Viral Metagenomics
Plasma and CSF from 13 horses with neurological signs and plasma and respiratory swabs from
another 14 horses with respiratory signs tested negative for a panel of known equine pathogens (see
Study Samples in Materials and Methods).
These samples were analyzed by viral metagenomics in 12 pools of 4–5 samples each. A total of
15.2 million reads were generated for an average number of reads of ~1.1 million per pool. The raw
sequence data for each pool are available at NCBI’s Short Reads Archive under GenBank accession
number SRP120619.
Viruses detected with BLASTx translated protein matches (E score <10−10) were: a novel
copiparvovirus in three pools, bovine serum-associated parvovirus (bosavirus) in three pools, horse
parvovirus-CSF in two pools, and equine hepacivirus, equine pegivirus D, and equid gammaherpesvirus
2 and 5 in one pool each (Table 1).
The most commonly detected eukaryotic viral reads belonged to the Copiparvovirus genus of
Parvoviridae family with a frequency ranging from 0.66% to 3.68% of total reads. Novel (divergent)
copiparvovirus reads from three pools generated contigs ranging in size from 1417 to 5158 nt that
showed closest translated aa identity of 42.5 to 43.9% to NS1 and 43.5 to 44.9% to VP1 encoded by the
horse parvovirus-CSF genome (GenBank KR902500). This virus was named equine copiparvovirus
(eqcopivirus or EqCoPV).
Reads matching the previously described horse parvovirus-CSF genome were also detected. This
parvovirus was reported in the CSF of a horse with neurological signs [20].. A partial NS1 sequence of
this virus was also recently reported from a thoroughbred in China sampled in 2018 (QCF41227.1). Two
of the three pools containing the novel eqcopivirus also showed the presence of horse parvovirus-CSF
although with fewer reads. Both 37.5% and 60.5% of the horse parvovirus-CSF genomes could be
assembled using reads from these plasma pools showing 98.8% and 97% nucleotide similarity with the
original horse parvovirus-CSF derived genome in GenBank (KR902500).
Equine hepacivirus contigs of 522 and 657 nucleotides were also generated from seven reads in a
pool of plasma from horses with neurological signs. Contigs showed 97.9–98.7% nt identities to equine
hepacivirus (JQ434008) in GenBank.
A total of 13 different equid gammaherpesvirus 2 and 5 contigs, ranging in size from 446 to 1049
nucleotides, were generated from 120 and 25 reads in a pool of swab from horses with respiratory
symptom. Contigs showed 92–100% aa identities to equid gammaherpesvirus 2 (NC_001650.2) and 5
(NC_026421.1) in GenBank.
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Two partial equine pegivirus contigs of 446 and 903 nucleotides were generated from 317 reads in
a pool of plasma from horses with respiratory signs. Contigs showed 92–93% nt identities to equine
pegivirus 1 (KC410872) in GenBank.
Another copiparvovirus (bosavirus) was also detected but likely originated from fetal bovine
Plasma spiked into the respiratory swab viral transport medium. A near complete genome from a
respiratory swab pool showed 100% aa identity to that of bosavirus in GenBank (NC_031959) [26].
3.2. Generation of Near-Full Length Genomes of Novel Equine Copiparvovirus (Eqcopivirus)
The length of the longest eqcopivirus contig was 5159 nucleotides (nt) with typical copiparvovirus
genome organization of two complete major ORFs (NS and VP), and 5’ and 3’ UTRs missing the
genome’s terminal hairpin sequences. The study strain had a 43.8% G+C content and it has a nt
distribution of 39.3% A, 16.8% T, 22.8% G, and 20.9% C.
The expected NS1 ATP- or GTP-binding Walker A loop motif (GxxxxGKT/S; GPPSVGKS) and
Walker B motif (EE) were all found [27,28]. The phospholipase A2 (PLA2) catalytic residues (HDLGY)
and its highly conserved calcium-binding site (YTGPG) were also found at the N-terminus of the
capsid protein [29].
The predicted capsid proteins (VP1) of eqcopivirus showed closest aa identity of 43.4% (coverage:
77%) and 37.7% (coverage: 53%) to the corresponding proteins of its two closest relative the horse
parvovirus-CSF (KR902500) and equine parvovirus-H (MG136722), respectively. The nonstructural
protein (NS1) proteins had 43.4% (coverage: 74%) and 31.3% (coverage: 69%) aa identity to the
corresponding proteins of horse parvovirus-CSF (KR902500) and equine parvovirus-H (MG136722),
respectively. The ORF structure of eqcopivirus is shown in Figure 1A. Phylogenetic analyses of the
eqcopiviruses and bosavirus NS and VP proteins acquired in this study are shown in Figure 1B.
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3.3. Real-Time PCR Results
Real-time PCR assays were developed to the three parvoviruses detected here using HTS
(horse parvovirus-CSF, novel eqcopivirus, and bosavirus). Real-time PCR assays using previously
described conditions were used for equine hepaciviruses and the recently identified hepatotropic
equine parvovirus-H pathogen [12,19]. These PCR assays were then used on all 94 available equine
plasma, CSF, and respiratory swabs (from 68 horses) described above. The positive detections are
shown with Ct values that are inversely proportional to their nucleic acid target concentration (Table 2).
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Table 2. Real-time PCR results and Ct values. Within each of the 2 clinical groups different samples
from the same animals are labeled with the same number. Lowest to highest Ct labeled red to white.
Sample Type Pool EquineHepacivirus EqPV-H Eqcopivirus
Horse
Parvovirus-CSF Bosavirus
N
eu
ro
lo
gi
ca
lS
ig
ns
Plasma 1
Pool1
30.32
Plasma 2
Plasma 3
Plasma 4 27.7 20
Plasma 5
Pool2
Plasma 6 34.65 36.73
Plasma 7 23.6
Plasma 8
Plasma 9
Pool3
Plasma 10 33.82
Plasma 11
Plasma 12
Plasma 13
CSF 1
Pool4
CSF 2
CSF 3
CSF 4
CSF 5
Pool5
CSF 6
CSF 7
CSF 8
CSF 9
Pool6
30
CSF 10
CSF 11
CSF 12 36.5
CSF 13
R
es
pi
ra
to
ry
Si
gn
s
Plasma 1
Pool7
37.78
Plasma 2
Plasma 3
Plasma 4 34
Plasma 5 27.53
Plasma 6
Pool8
Plasma 7 30.16
Plasma 8
Plasma 9 34.6 34.01 21
Plasma 10
Pool9
Plasma 11
Plasma 12
Plasma 13
Plasma 14
Swab 1
Pool10
26.85
Swab 2 25.65
Swab 3 25.28 26.4
Swab 4 36.7 26.82
Swab 6
Pool11
25.02
Swab 7 32.62 27.75
Swab 8 25.57
Swab 9 26.24
Swab 10
Pool12
21.2 24.92
Swab 11 23.1 23.37
Swab 12 26.63
Swab 13 32.41 23.29
Swab 14 37.2 26 25.3
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Table 2. Cont.
Sample Type Pool EquineHepacivirus EqPV-H Eqcopivirus
Horse
Parvovirus-CSF Bosavirus
H
ea
lt
hy
C
on
tr
ol
G
ro
up
Plasma 1
Plasma 2 16.8
Plasma 3 21.8 37.3
Plasma 4 26.5
Plasma 5 36.5
Plasma 6
Plasma 7
Plasma 8
Plasma 9
Plasma 10
Plasma 11 28.08
Plasma 12
Plasma 13
Plasma 14 30.21
Plasma 15
Plasma 16
Plasma 17 26.08
Plasma 18
Plasma 19 23.02 36.9
Plasma 20
Plasma 21
Plasma 22
Plasma 23 23.53
Plasma 24
Plasma 25 25.11
Plasma 26
Plasma 27 33.83
Plasma 28
Plasma 29
Plasma 30
Plasma 31 33.99 30.09
Plasma 32 37.93 26.34 30.1
Plasma 33
Plasma 34
Plasma 35
Plasma 36 33.22
Plasma 37
Plasma 38
Plasma 39
Plasma 40 34.69 28.63
Plasma 41 30.12
Bosavirus (originally reported in bovine serum pools) [26] was detected in every one of the 13
respiratory swab samples with nearly identical CT value. These respiratory swabs had been preserved
in a transport media spiked with fetal bovine serum from the same commercial product. None of the
other equine samples (plasma and CSF) were preserved using fetal bovine serum and none showed
the presence of bosavirus parvovirus DNA by HTS or real-time PCR. Because bosavirus was originally
described as a contaminant of fetal bovine serum [26] we ascribe its detection to the use of contaminated
fetal bovine serum spiked into every respiratory swab sample.
The most commonly detected virus was the new eqcopivirus detected in 16/94 samples (14/68
horses). Its highest detection rate was in 4/14 plasmas from respiratory cases. Three of the four plasma
positive samples also had matching respiratory swabs, two of which were also positive indicating
the presence of eqcopivirus genomes in both plasma and respiratory swabs and revealing a possible
mode of transmission through respiratory fluids (Table 2). When the eqcopivirus prevalence in plasma
samples from respiratory cases (4/14 or 28.6%) was compared to that in plasma from healthy animals
(7/41 or 17%) the difference (measured using Fisher’s exact test) yielded a non-significant p value of
0.443 (Table 3). The next two most prevalent viruses were the hepatotropic parvovirus-H and equine
hepacivirus both found in 11/89 samples including 3 co-infections. All detections were in plasma
samples except for two hepacivirus positive respiratory swabs (Table 2). No evidence of higher virus
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prevalence was detected between cases and health controls (Table 3). Lastly the horse parvovirus-CSF
was detected in eight samples from eight horses in all sample types (plasma, CSF, respiratory swabs)
also with no obvious association with either neurological or respiratory disease when comparing
prevalence in plasma samples (Table 3). When the real-time PCR Ct values were compared (using
unpaired two tailed T-test with Welsh’s correction) no statistically significant differences were found
between cases and controls.
Table 3. Rate of real-time PCR detection for equine viruses and association with unexplained
neurological or respiratory diseases using Fisher’s exact test.
Neuro
Plasma
n = 13
Neuro
CSF
n = 13
Respiratory
Plasma
n = 14
Respiratory
Swab
n = 13
Healthy
Control
Plasma
n = 41
Total
Samples
n = 94
P Value =
Plasma
Neurological
Versus
Healthy
P Value =
Plasma
Respiratory
Versus
Healthy
Equine
flavivirus 3 (23%) 0 0 2 (15%) 6 (15%) 11 (12%) 0.32 0.67
EqPV-H 2 (15%) 0 2 (15%) 0 7 (17%) 11 (12%) 1 1
Eqcopivirus 1 (7%) 1 (7%) 4 (30%) 3 (23%) 7 (17%) 15 (16%) 0.443 0.663
Horse
parvovirus-CSF 1 (7%) 1 (7%) 1 (7%) 3 (23%) 2 (5%) 8 (8.5%) 1 1
4. Discussion
Virus metagenomics analysis of plasma, CSF and respiratory swabs from horses with unexplained
neurological and respiratory signs showed the presence of three parvoviruses, one of which (bosavirus)
was likely introduced by the addition of fetal bovine serum to the respiratory swabs transport medium.
Additionally detected by metagenomics were equine hepacivirus, equine pegivirus [19], and equine
herpesvirus 2 and 5. Another copiparvovirus (equine parvovirus-H) was also detected using real-time
PCR (but not by HTS) likely due to its lower concentration as reflected by higher real-time PCR
CT values.
The presence of viral nucleic acids detected by PCR or HTS does not prove the presence of infectious
viruses. Nonetheless, the repeated detection of viral genomes in nuclease-treated, presumably sterile
samples such as plasma and CSF, and the typically rapid clearance of viral particles from the circulation
by the liver support the possibility of active replication [30–32].
When the prevalence of the plasma-associated viruses was determined in individual samples
using real-time PCR none showed a statistically higher rate of detection or higher viral loads as
determined by Ct when comparing plasma from 13 neurological or 14 respiratory cases to plasma
from 41 healthy horses. Only the new eqcopivirus showed a trend toward a higher rate of detection
in plasma from unexplained respiratory cases (30% versus 17%) (p = 0.443). CSF and respiratory
swabs where available only from neurological or respiratory cases respectively. The rate of virus
detection could therefore not be measured in these anatomical compartments in healthy animals.
Horse parvovirus-CSF and eqcopivirus were also detected in 1/13 (different) CSF samples and in 3/13
(different) respiratory swabs each. The initial characterization of horse parvovirus-CSF genome was
also from a CSF sample from a different unexplained neurological case [20].
PCR previously showed EqPV-H DNA to be present in the plasma of 13% healthy horses in the
US [2] and 12% of healthy race horses in China [13], rates of viremia similar to that detected here in
6/41 (15%) of healthy horses.
The Parvoviridae family consists of non-enveloped, icosahedral, viruses with single stranded DNA
genomes of 4 to 6 Kb [27,28]. Eight ICTV approved genera, including Copiparvovirus, are currently
included in the Parvoviridae family [33]. The eqcopivirus genome described here represents the third
parvovirus species confirmed to infect horses by virtue of detection in multiple equine plasma, CSF,
and respiratory swab samples. That all parvoviruses identified to date in horses belong only to the
copiparvovirus genus is somewhat unexpected and future studies are likely to expand the list of known
equine parvoviruses. While a higher rate of eqcopivirus DNA detection was found in the plasma
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of horses with unexplained respiratory signs (30%) versus plasma from healthy horses (17%) that
difference, based on the limited number of samples tested, was not statistically significant. Because CSF
and respiratory swabs from healthy animals were not available only PCR results from plasma could be
compared for disease association. Viruses resulting in neurological and respiratory disease may be
expected to be present in CSF or respiratory fluids respectively as were both horse parvovirus-CSF
and eqcopivirus. The collection of CSF and respiratory swabs samples from healthy animals may be
necessary to better test for possible associations between these copiparvoviruses and unexplained
neurological and respiratory signs. The now repeated detection of horse parvovirus-CSF [20] (n = 2)
and eqcopivirus (n = 1) in CSF of horses indicates a possible role for these viruses in these neurological
signs which will require further studies. The availability of eqcopivirus genome sequences will now
also allow the design of hybridization probes to determine whether infected cells can be identified in
fixed brain or lung tissues from animals with unexplained neurological or respiratory signs.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/11/10/942/s1,
Table S1: Real time PCR conditions.
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